E
Willow Biosciences Inc. WLLW.TO
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 11/18/2024Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 11/18/2024 due to a noticeable decline in the valuation index, growth index and total return index. Operating cash flow declined 24.27% from -$535.7 to -$665.7.
D
Sell 10/24/2024Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 10/24/2024 due to an increase in the volatility index.
E
Sell 10/9/2024Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 10/9/2024 due to a decline in the volatility index.
D
Sell 9/19/2024Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 9/19/2024 due to an increase in the total return index and volatility index.
E
Sell 9/4/2024Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 9/4/2024 due to a decline in the volatility index.
D
Sell 8/16/2024Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 8/16/2024 due to a large increase in the growth index and volatility index. Total revenue increased 1,883.6% from $37.8 to $749.8, operating cash flow increased 58.71% from -$1.3M to -$535.7, and EBIT increased 41.99% from -$1.82M to -$1.06M.
E
Sell 3/27/2024Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 3/27/2024 due to a decline in the volatility index and total return index.
D
Sell 3/8/2024Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 3/8/2024 due to an increase in the total return index and valuation index.
E
Sell 2/22/2024Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 2/22/2024 due to a decline in the valuation index.
D
Sell 2/7/2024Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 2/7/2024 due to a substantial increase in the growth index, total return index and volatility index. Total revenue increased 400% from $100.5 to $502.5, EBIT increased 38.53% from -$2.72M to -$1.67M, and earnings per share increased from -$0.0216 to -$0.0134.
E
Sell 10/23/2023Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 10/23/2023 due to a decline in the volatility index and total return index.
D
Sell 10/6/2023Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 10/6/2023 due to an increase in the total return index and volatility index.
E
Sell 9/18/2023Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 9/18/2023 due to a decline in the total return index and volatility index.
D
Sell 8/31/2023Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index.
E
Sell 8/14/2023Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.04 to 0.1, and the quick ratio declined from 6.57 to 3.83.
D
Sell 7/27/2023Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 7/27/2023 due to an increase in the volatility index.
E
Sell 7/10/2023Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 7/10/2023 due to a decline in the volatility index and total return index.
D
Sell 6/21/2023Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 6/21/2023 due to an increase in the total return index and volatility index.
E
Sell 5/8/2023Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 5/8/2023 due to a decline in the volatility index and growth index.
D
Sell 4/3/2023Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index and total return index.
E
Sell 3/14/2023Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell 2/9/2023Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell 2/8/2023Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell 11/10/2022Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D from D- on 11/10/2022 due to a large increase in the growth index and valuation index. EBIT increased 10.12% from -$3.53M to -$3.17M, and operating cash flow increased 6.14% from -$2.67M to -$2.51M.
D
Sell 8/17/2022Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to D- from D on 8/17/2022 due to a significant decline in the efficiency index, valuation index and growth index. Earnings per share declined from -$0.019 to -$0.0235, total capital declined 12.75% from $22.29M to $19.45M, and operating cash flow declined 10.64% from -$2.41M to -$2.67M.
D
Sell 6/23/2022Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to D from D+ on 6/23/2022 due to a decline in the volatility index and total return index.
D
Sell 5/20/2022Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D+ from D on 5/20/2022 due to a significant increase in the efficiency index, valuation index and growth index. Net income increased 43.17% from -$4.12M to -$2.34M, earnings per share increased from -$0.0334 to -$0.019, and operating cash flow increased 40% from -$4.02M to -$2.41M.
D
Sell 5/5/2022Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and valuation index.
D
Sell 4/20/2022Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0238 to -$0.0334, debt to equity increased from 0.01 to 0.02, and operating cash flow declined 20.15% from -$3.35M to -$4.02M.
D
Sell 1/28/2022Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D from D- on 1/28/2022 due to an increase in the total return index and volatility index.
D
Sell 1/13/2022Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to D- from D on 1/13/2022 due to a decline in the volatility index and total return index.
D
Sell 12/23/2021Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D from D- on 12/23/2021 due to an increase in the volatility index.
D
Sell 12/8/2021Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to D- from D on 12/8/2021 due to a decline in the volatility index and total return index.
D
Sell 11/17/2021Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D from D- on 11/17/2021 due to an increase in the growth index and solvency index. Debt to equity declined from 0.02 to 0.01, and operating cash flow increased 18.18% from -$4.09M to -$3.35M.
D
Sell 11/8/2021Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and growth index. Operating cash flow declined 50.25% from -$2.72M to -$4.09M, and EBIT declined 25.65% from -$3.74M to -$4.7M.
D
Sell 11/16/2020Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D from D- on 11/16/2020 due to a substantial increase in the growth index. Earnings per share increased from -$0.0921 to -$0.0751.
D
Sell 11/9/2020Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 11/9/2020 due to a noticeable increase in the total return index, volatility index and valuation index.
E
Sell 8/14/2020Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 8/14/2020 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0134 to -$0.0939, and the quick ratio declined from 9.7 to 8.97.
D
Sell 5/4/2020Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E+ on 5/4/2020 due to an increase in the volatility index and growth index.
E
Sell 3/26/2020Downgrade
Willow Biosciences Inc. (WLLW.TO) was downgraded to E+ from D- on 3/26/2020 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 196.05% from -$1.12M to -$3.31M, earnings per share declined from -$0.0106 to -$0.0299, and net income declined 181.8% from -$832.6 to -$2.35M.
D
Sell 1/2/2020Upgraded
Willow Biosciences Inc. (WLLW.TO) was upgraded to D- from E on 1/2/2020 due to an increase in the volatility index, valuation index and total return index.
E
Sell 10/1/2019Upgraded
Willow Biosciences Inc. (WLLW) was upgraded to E from E- on 10/1/2019 due to a noticeable increase in the solvency index, valuation index and efficiency index. Total capital increased 3,073.89% from $618.1 to $19.62M, the quick ratio increased from 1.12 to 13.23, and debt to equity declined from 0.85 to 0.02.
E
Sell 7/8/2019None
Willow Biosciences Inc. (WLLW.TO) was downgraded to E- from U on 07/08/2019.
Weiss Ratings